News from the Alzheimer's Association International Conference (AAIC)

News from the Alzheimer's Association International Conference (AAIC)

A note from Mikey Hoag

Recently, I joined 10,000 researchers from 99 countries both in person and virtually to learn more about the latest in Alzheimer's and dementia research. After participating in AAIC, I am even more humbled by the speed and momentum the field has – it truly is an exciting time in research, and Part the Cloud is at the forefront of this scientific revolution in Alzheimer's. Watch this video to get a snapshot of the energy and hope felt at AAIC22.

I spoke with all of our Part the Cloud-funded researchers who were at the Alzheimer's Association International Conference (AAIC). Many of them told me that they would not have been able to move their research forward if it wasn't for the support of Part the Cloud grant funding. We are collecting their stories so we can share more about the impact of your support on their research and how it is going to help get promising therapies to those living with Alzheimer's faster.

Two Part the Cloud-funded researchers were plenary speakers, which is notable because only a few are selected every year to cover important topics within the field. Krista Lanctot, Ph.D., a two-time awardee who is featured in the latest Impact Report, delivered a plenary presentation on “Apathy in Neurodegenerative Diseases,” and Frank Longo, M.D., Ph.D., spoke about “Next-Generation Alzheimer's Therapeutics: Leveraging Deep Biology.” Plenary sessions are dedicated times that serve as opportunities for participation from all attendees. Having two of the nine speakers funded by Part the Cloud demonstrates we're fueling and funding visionaries in the field.

I also had the opportunity to speak with the experts who review the applications for Part the Cloud grants. There are reviewers from Mayo Clinic, Mount Sinai, Johns Hopkins, Massachusetts General Hospital, UCSF, Yale, NYU, several for-profit companies, and other premier institutions. Additionally, these reviewers are across the globe spanning 10 countries. One reviewer noted, “Part the Cloud has the top experts in the field reviewing these applications.” That's one of the reasons Part the Cloud is transformative and innovative in the field – the grant process is competitive, we have diversity of thoughts and approaches, we are grounded in solid science, and we are guided by decades of expertise by the top leaders in the industry.

Where we are today from where we started a decade ago is beyond my wildest dreams. AAIC confirmed that our impact is reverberating throughout the globe. With your help, we are truly making a difference. I am incredibly grateful for your continued support because there is so much more to be done. It isn't only scientists who are leading the way to a cure; your support is helping push research forward, too.

Together, we will Part the Cloud.

Mikey Hoag
Founder, Part the Cloud

Mikey Hoag and Dr. Suzanne Craft

Mikey Hoag, Lauren Koenig, and Dr. Ross Paterson

Mikey Hoag, Lauren Koenig, and Dr. Hung-Kai (Kevin) Chen

In the news

Reporting from AAIC, T3D Therapeutics Dr. John Didsbury reported interim results from the Phase 2 trial of T3D-959, which aims to address insulin resistance in the brain and restore healthy brain metabolism. Read more from NBC News, “As new Alzheimer's drugs have failed, scientists are shifting focus to other potential causes.”

Part the Cloud was represented throughout AAIC with a number of presentations and sessions by awardees, including:

  • Peter Ljubenkov: “Introduction to Veri-T: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Verdiperstat in Patients with svPPA Due to FTLD-TDP”

  • Stephen Cunnane: “Brain energy rescue with ketones improves cognitive outcomes in MCI” and “Ketones bypass glucose dysregulation in the brain: implications for treating AD”

  • Alireza Faridar: “Ex vivo Expanded Human Regulatory T Cells Modify Neuroinflammation in a Preclinical Model of Alzheimer's disease”

  • Paul Edison: “Is cortical grey matter diffusivity an early biomarker for neuronal damage?” and “Longitudinal trajectory of microglial activation and astrocyte activation” and “Longitudinal evolution of neuropathological substrates of Alzheimer's disease in obese patients”

  • Miia Kivipelto: “From FINGER to MET-FINGER: metformin and lifestyle intervention for multimodal precision prevention of dementia”

  • Dieter Willbold: “Aβ oligomer elimination decreases tau oligomer concentration in CSF and enhances cognition in cognitively impaired aged Beagle dogs - a model of sporadic Alzheimer's disease” and “Ex vivo target engagement of the Abeta oligomer disassembling compound RD2 in patient derived brain homogenates.”

  • Davangere P Devanand: “Neuropsychiatric Symptoms and Neuropathological diagnoses of Alzheimer's Disease and Related Dementias”

Dr. Hung-Kai (Kevin) Chen

Dr. Krista Lanctot


To fund Alzheimer's research with the highest probability of slowing, stopping or ultimately curing Alzheimer's disease.